Subodh Verma


Scientist, Keenan Research Centre for Biomedical Science


Please note: Dr. Verma will not take students in summer 2019.

Dr Subodh Verma is an internationally renowned cardiac surgeon-scientist and Professor at the University of Toronto. He is the Canada Research Chair in Cardiovascular Surgery and a past recipient of the Howard Morgan Award for Distinguished Achievements in Cardiovascular Research and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. He served as Canada Research Chair in Atherosclerosis for 10 years from 2007-2017. He is an appointee of the
American Association of Thoracic Surgeons (AATS) and a member of the College of New Scholars, Artists and Scientists, Royal Society of Canada. According to Google Scholar, Dr Verma’s work has been cited nearly 28,000 times resulting in an h-index of 82.

Dr Verma has published numerous times in prestigious journals like the NEJM, Lancet, Circulation, JBC, JACC, Nature, and JCI. He continues to be an active contributor to several CCS guidelines and co-authored the 2018 Diabetes Canada guidelines and 2018 AATS consensus guidelines on bicuspid aortic valve-related aortopathy. Dr Verma has served on the American Heart Association Council on Cardiovascular Surgery and Anesthesia since 2008.

Dr Verma has leadership roles on 7 ongoing global heart failure trials in diabetes – Dapa-HF, DELIVER, DETERMINE-A, DETERMINE-B, EMPEROR-Preserved, EMPEROR-Reduced and SOLOIST-WHF – as well as the SELECT (semaglutide) and CLEAR SYNERGY (OASIS 9) trials. He oversees the CardioLink platform that is conducting surgically oriented RCTs and translational studies.

Dr Verma oversees a dynamic pre-clinical and translational research team that leverages pre-clinical disease models and clinical trial-derived data to identify novel mediators of cardiovascular and cardiometabolic disease as well as answer timely and relevant healthcare questions. This research has yielded 2 United States patents and is currently supported by the Canadian Institutes of Health Research (CIHR) and HSF.


Recent Publications

  1. O'Meara, E, McDonald, M, Chan, M, Ducharme, A, Ezekowitz, JA, Giannetti, N et al.. CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. Can J Cardiol. 2020;36 (2):159-169. doi: 10.1016/j.cjca.2019.11.036. PubMed PMID:32036861 .
  2. Verma, S, Ji, Q, Bhatt, DL, Mazer, CD, Al-Omran, M, Inzucchi, SE et al.. The Association Between Uric Acid Levels and Cardio-renal Outcomes and Death in Patients with Type 2 Diabetes: A Subanalysis of EMPA-REG OUTCOME. Diabetes Obes Metab. 2020; :. doi: 10.1111/dom.13991. PubMed PMID:32030863 .
  3. Chowdhury, B, Luu, AZ, Luu, VZ, Kabir, MG, Pan, Y, Teoh, H et al.. The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension. Biochem. Biophys. Res. Commun. 2020; :. doi: 10.1016/j.bbrc.2020.01.015. PubMed PMID:31980166 .
  4. Byrne, NJ, Matsumura, N, Maayah, ZH, Ferdaoussi, M, Takahara, S, Darwesh, AM et al.. Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure. Circ Heart Fail. 2020;13 (1):e006277. doi: 10.1161/CIRCHEARTFAILURE.119.006277. PubMed PMID:31957470 .
  5. Butler, J, Handelsman, Y, Bakris, G, Verma, S. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. Eur. J. Heart Fail. 2020; :. doi: 10.1002/ejhf.1708. PubMed PMID:31926059 .
  6. Sharma, A, Verma, S. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus. Can J Diabetes. 2020;44 (1):93-102. doi: 10.1016/j.jcjd.2019.09.003. PubMed PMID:31882322 .
  7. Verma, S, Bhatt, DL. Does Interleukin-17A Blockade Have a Potential Clinical Role to Reduce Cardiovascular Risk in Psoriasis?. Can J Cardiol. 2020;36 (1):24-26. doi: 10.1016/j.cjca.2019.11.011. PubMed PMID:31874749 .
  8. Verma, S. The DAPA-HF trial marks the beginning of a new era in the treatment of heart failure with reduced ejection fraction. Cardiovasc. Res. 2020;116 (1):e8-e10. doi: 10.1093/cvr/cvz328. PubMed PMID:31850505 .
  9. Kang, S, Verma, S, Hassanabad, AF, Teng, G, Belke, DD, Dundas, JA et al.. Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results. Can J Cardiol. 2019; :. doi: 10.1016/j.cjca.2019.08.033. PubMed PMID:31837891 .
  10. Böhm, M, Slawik, J, Brueckmann, M, Mattheus, M, George, JT, Ofstad, AP et al.. Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial. Eur. J. Heart Fail. 2020;22 (1):126-135. doi: 10.1002/ejhf.1663. PubMed PMID:31820559 .
Search PubMed

Affiliations & Other Activities

  • Staff Surgeon, Division of Cardiology , St. Michael’s Hospital
  • Professor, Department of Surgery and Pharmacology & Toxicology, University of Toronto